Opinion|Videos|August 19, 2024

Patient Access Advocacy for BTK Inhibitors

A panel of specialists discuss patient access advocacy for BTK inhibitors.

Video content above is prompted by the following:

  • How do changes in patient out-of-pocket costs under the IRA influence treatment and sequencing decisions?
  • What strategies can healthcare providers use to advocate for patient access to BTK inhibitors?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo